Nature GeneticsCancer BiologyPeer-reviewed journal article
U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations
David M. WalteriD, Katherine Cho, Smruthy SivakumariD, Daniel Denney, Iris TIENLYNN. LeeiD, Anders B. DohlmaniD, Jakob M. Heinz, Ethan Shurberg, Kevin X. Jiang, Akansha A. GuptaiD, Garrett Michael FramptoniD, Matthew M. MeyersoniD
Abstract
The mechanisms by which somatic mutations of splicing factors, such as U2AF1S34F in lung adenocarcinoma, contribute to cancer pathogenesis are not well understood. Here, we used prime editing to modify the endogenous U2AF1 gene in lung adenocarcinoma cells and assessed the resulting impact on alternative splicing. These analyses identified KRAS as a key target modulated by U2AF1S34F. One specific KRAS mutation, G12S, generates a cryptic U2AF1 binding site that leads to skipping of KRAS exon 2 and generation of a non-functional KRAS transcript. Expression of the U2AF1S34F mutant reverts this exon skipping and restores KRAS function. Analysis of cancer genomes reveals that U2AF1S34F mutations are enriched in KRASG12S-mutant lung adenocarcinomas. A comprehensive analysis of splicing factor/oncogene mutation co-occurrence in cancer genomes also revealed significant co-enrichment of KRASQ61R and U2AF1I24T mutations. Experimentally, KRASQ61R mutation leads to KRAS exon 3 skipping, which in turn can be rescued by the expression of U2AF1I24T. Our findings provide evidence that splicing factor mutations can rescue splicing defects caused by oncogenic mutations. More broadly, they demonstrate a dynamic process of cascading selection where mutational events are positively selected in cancer genomes as a consequence of earlier mutations.
- organism: human
- assay: spatial transcriptomics
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
- approach: statistical model
- Citations
- 4
- FWCI
- 4.18
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Wild-type U2AF1 antagonizes the splicing program characteristic of U2AF1-mutant tumors and is required for cell survival
Dennis Liang Fei, Hayley Motowski, … Harold Varmus·bioRxiv·Aug 24, 2016
- U2AF1 S34F enhances tumorigenic potential of lung cells by exhibiting synergy with KRAS mutation and altering response to environmental stress
Cindy E Liang, Eva Hrabeta‐Robinson, … Angela Norie Brooks·bioRxiv·Sep 11, 2024
- U2AF1 mutations alter splice site recognition in hematological malignancies
Janine O Ilagan, Aravind Ramakrishnan, … Robert K Bradley·bioRxiv·Sep 29, 2014
- The splicing factor U2AF1 contributes to cancer progression through a non-canonical role in translation regulation
M. Palangat, D. Anastsakis, … D. Larson·bioRxiv·Jul 18, 2018
- U2AF1 is a haplo-essential gene required for cancer cell survival
B. A. Wadugu, A. Heard, … M. J. Walter·Journal of Clinical InvestigationPeer-reviewed·Nov 1, 2021
- Multi-omics profiling of U2AF1 mutants dissects pathogenic mechanisms affecting RNA granules in myeloid malignancies
G. Biancon, P. Joshi, … S. Halene·bioRxiv·Apr 22, 2021